More Powerful Than Ozempic? Eli Lilly’s Experimental Drug Shows Up To 28% Weight Loss
Eli Lilly’s experimental weight-loss drug retatrutide, nicknamed the “Godzilla” of obesity treatments, has delivered striking results in late-stage trials. In people with obesity or overweight, the highest dose produced
Ni Tanya Dutt··29K nabasa
More Powerful Than Ozempic? Eli Lilly’s Experimental Drug Shows Up To 28% Weight Loss
Eli Lilly’s experimental weight-loss drug retatrutide, nicknamed the “Godzilla” of obesity treatments, has delivered striking results in late-stage trials. In people with obesity or overweight, the highest dose produced average weight loss of more than 28% over 80 weeks, roughly twice the typical results seen with semaglutide (the active ingredient in Ozempic and Wegovy) in earlier obesity studies.
The findings have generated significant interest because retatrutide works differently from current GLP-1 drugs. While Ozempic primarily targets one hormone pathway, this next-generation candidate activates three.
Retatrutide is not yet approved for public use, and there has been no head-to-head trial directly comparing it with Ozempic.
What is Retatrutide?
Retatrutide is a once-weekly investigational injection that targets three hormone pathways: GLP-1, GIP and glucagon. This is why it is often referred to as a triple agonist.
Ozempic, meanwhile, contains semaglutide, which activates the GLP-1 receptor. GLP-1-based medicines can help regulate blood sugar and appetite, while retatrutide is designed to act on an additional GIP pathway and the glucagon receptor, which is involved in energy expenditure and metabolism.
How Does Retatrutide Differ From Ozempic?
Retatrutide is a triple agonist. It stimulates the GLP-1 receptor (the same target as Ozempic), the GIP receptor, and the glucagon receptor. Together, these pathways influence appetite, blood-sugar control, and energy expenditure. The multi-hormone approach is designed to produce greater reductions in body weight than single-pathway medicines.
How Much Weight Did People Lose with Retatrutide?
The latest Phase 3 TRIUMPH-2 results, published in The Lancet in September 2026, involved adults with overweight or obesity and type 2 diabetes.
After 80 weeks, participants receiving the highest 12 mg dose of retatrutide lost an average of 20.8% of their body weight. Those receiving 9 mg lost 19.1%, while the 4 mg group lost 12.7%. The trial also found improvements in HbA1c, with reductions of up to 1.6 percentage points.
An earlier Phase 3 trial, TRIUMPH-1, produced even larger reductions among people with obesity or overweight who did not have diabetes. At 80 weeks, those taking 12 mg lost an average of 28.3% of their body weight. In a selected extension group with BMI of at least 35, average weight loss reached 30.3% at 104 weeks.
Is Retatrutide Better Than Ozempic?
The comparison comes from looking at results from different clinical trials, rather than a direct retatrutide-versus-Ozempic study. That makes a straightforward 2X comparison scientifically inappropriate.
Previous studies of semaglutide have generally reported lower average weight reductions than the percentages seen with retatrutide in Lilly’s Phase 3 trials. However, differences in participants, trial design, treatment duration and doses can affect the results.
A direct comparison is still needed before researchers can determine how much more effective retatrutide is than existing medicines. A head-to-head Phase 3 trial comparing retatrutide with tirzepatide is also underway.
What Side Effects have Been Reported?
Retatrutide remains investigational. Eli Lilly has indicated it plans to submit the drug for U.S. regulatory review in 2027. Until then, it is not available for prescription.
Gastrointestinal side effects were among the most common issues reported. In the diabetes trial, diarrhea, nausea, constipation and vomiting occurred more frequently at higher doses. Researchers are also continuing to study body composition specifically how much of the lost weight is fat versus lean tissue, an important question as use of powerful weight-loss medicines expands.
What Does this Mean for People Considering Obesity Treatment?
The trial results suggest that the next wave of obesity medicines may deliver substantially greater weight reduction than today’s widely used GLP-1 drugs. For individuals with significant excess weight and related health conditions, larger average losses could translate into meaningful improvements in metabolic health, mobility and risk of complications.
However, experts stress that these are still clinical-trial findings. Longer-term safety data, real-world effectiveness, and the balance between fat and muscle loss will all shape how the drug is ultimately used if approved. Cost, access, and the need for ongoing lifestyle support will also remain practical considerations, as they are with current medicines.
For now, retatrutide represents a promising advance in a rapidly evolving field. Its ability to activate three hormone pathways has produced some of the largest average weight-loss percentages seen so far in obesity trials. Whether those results hold up in broader populations and over longer periods will determine if the “Godzilla” nickname becomes more than a headline.